GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xbrane Biopharma AB (OSTO:XBRANE) » Definitions » Price-to-Free-Cash-Flow

Xbrane Biopharma AB (OSTO:XBRANE) Price-to-Free-Cash-Flow : N/A (As of Dec. 11, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Xbrane Biopharma AB Price-to-Free-Cash-Flow?

As of today (2024-12-11), Xbrane Biopharma AB's share price is kr0.175. Xbrane Biopharma AB's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2024 was kr-0.76. Hence, Xbrane Biopharma AB's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Xbrane Biopharma AB's Price-to-Free-Cash-Flow or its related term are showing as below:

During the past 11 years, Xbrane Biopharma AB's highest Price-to-Free-Cash-Flow Ratio was 7.53. The lowest was 5.59. And the median was 6.74.

OSTO:XBRANE's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 36.58
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Xbrane Biopharma AB's Free Cash Flow per Share for the three months ended in Sep. 2024 was kr-0.03. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was kr-0.76.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -3.30% per year.

During the past 11 years, Xbrane Biopharma AB's highest 3-Year average Free Cash Flow per Share Growth Rate was 9.50% per year. The lowest was -125.90% per year. And the median was -15.75% per year.


Xbrane Biopharma AB Price-to-Free-Cash-Flow Historical Data

The historical data trend for Xbrane Biopharma AB's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xbrane Biopharma AB Price-to-Free-Cash-Flow Chart

Xbrane Biopharma AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Xbrane Biopharma AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Xbrane Biopharma AB's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Xbrane Biopharma AB's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xbrane Biopharma AB's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xbrane Biopharma AB's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Xbrane Biopharma AB's Price-to-Free-Cash-Flow falls into.



Xbrane Biopharma AB Price-to-Free-Cash-Flow Calculation

Xbrane Biopharma AB's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=0.175/-0.756
=N/A

Xbrane Biopharma AB's Share Price of today is kr0.175.
Xbrane Biopharma AB's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.76.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Xbrane Biopharma AB  (OSTO:XBRANE) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Xbrane Biopharma AB Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Xbrane Biopharma AB's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Xbrane Biopharma AB Business Description

Traded in Other Exchanges
Address
Retzius vag 8, Solna, SWE, 171 65
Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company follows drugs on already approved biological drugs that can be introduced at a lower price after the patent expires on the original drug. The company has a patented protein production platform with greater productivity than standard systems for producing proteins in E.coli host cells. Xbrane's product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration.

Xbrane Biopharma AB Headlines

No Headlines